Acura Pharmaceuticals, Inc.

Major Drugs - Palatine, IL, US

Acura Pharmaceuticals, Inc. Employees
John Gilkay

Director, EHS & Engineering

Contact John Gilkay

Ron Leech

Senior Director, Pharmaceutical Development & Quality

Contact Ron Leech

Albert Brzeczko

VP, Pharmaceutical Sciences

Contact Albert Brzeczko

Contact All Acura Pharmaceuticals, Inc. Employees
Acura Pharmaceuticals, Inc. Details

Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. We have discovered and developed three proprietary technology platforms to address abuse and misuse across multiple fronts. • Limitx™ Technology is designed to retard the release of active drug ingredients when an excess number of tablets are ingested. In 2014, we were awarded a $300,000 grant from the National Institute on Drug Abuse to advance early stage development of our Limitx Technology.• Aversion® Technology is a patented composition of commonly used active and inactive pharmaceutical ingredients providing abuse deterrent features to discourage common methods of pharmaceutical product misuse and abuse while providing effective pain relief.OXAYDO® Tablets (oxycodone HCl, CII), is the first approved product using Aversion® in the United States. On January 7, 2015, we entered into a Collaboration and License Agreement with Egalet US, Inc. granting to Egalet exclusive worldwide rights to manufacture and commercialize OXAYDO. OXAYDO is approved by the U.S. Food and Drug Administration for marketing in the United States in 5mg and 7.5mg strengths. Egalet launched OXAYDO in the United States late in the third quarter of 2015. • Impede® Technology is a combination of inactive ingredients that prevent the extraction or disrupt the direct conversion of pseudoephedrine from commonly used decongestant tablets into methamphetamine. NEXAFED® Decongestant with Impede Technology was launched into the United States market in December 2012 followed by NEXAFED Sinus Pressure + Pain in February 2015. We have multiple pseudoephedrine products in development utilizing Impede Technology.

Acura Pharmaceuticals, Inc. logo, Acura Pharmaceuticals, Inc. contact details
Website: acurapharm.com
Employees: 20 - 49
HQ: 847-705-7709
Location: Palatine, IL, US
Revenue: 1 - 2.5 Million
B2B Biotechnology Healthcare Pharmaceuticals Major Drugs Pharmaceutical Preparations
Acura Pharmaceuticals, Inc. Technologies
Load Balancers

Apache

CMS

WordPress.org

Web Performance Monitoring

New Relic

Hosting

GoDaddy Hosting

Search Marketing

Adobe Marketing Cloud

Other

Mobile Friendly

View All Technologies Used At Acura Pharmaceuticals, Inc.

Contacting Acura Pharmaceuticals, Inc.: Connect with Executives and Employees

Get in Touch with Acura Pharmaceuticals, Inc. Executives and Employees

Connecting with Acura Pharmaceuticals, Inc.'s Executives and Workforce

Accessing Contact Information for Acura Pharmaceuticals, Inc. Executives

Connecting with Acura Pharmaceuticals, Inc.: Reach Out to Their Team

Discover How to Contact Acura Pharmaceuticals, Inc. Executives and Staff

Looking to connect with Acura Pharmaceuticals, Inc. executives or employees?

Seeking to Get in Touch with Acura Pharmaceuticals, Inc. Executives or Staff?

Want to Reach Out to Acura Pharmaceuticals, Inc. Executives or Team Members?

In Search of Contact Details for Acura Pharmaceuticals, Inc. Professionals?

Connecting with Acura Pharmaceuticals, Inc.: Contacting Executives and Staff

Browse companies
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z